Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1010 | 995 | 942 | 1192 | 1323 | - |
Fund Return | 0.96% | -0.55% | -5.77% | 6.02% | 5.75% | - |
Place in category | 2560 | 2537 | 2445 | 958 | 778 | - |
% in Category | 96 | 95 | 96 | 49 | 54 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cleome Index USA Equities I USD Acu | 2.23B | 10.19 | 12.03 | - | ||
Cleome Index USA Equities Z USD Acc | 2.23B | 6.76 | 10.40 | 12.02 | ||
RBC Lux GlblEqFocus Class C USD Cap | 1.74B | 1.00 | 6.13 | - | ||
RBC Lux GlblEqFocus Class A USD Cap | 1.74B | 0.54 | 4.97 | - | ||
Cleome Index USA Eq C USD Inc | 2.23B | 9.68 | 7.99 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cap Group New Perspective lux C | 13.34B | 8.20 | 5.30 | - | ||
Capital Group New Perspective Fundu | 13.34B | 8.02 | 4.73 | 10.38 | ||
Cap Group New Perspective lux ZL | 13.34B | 8.03 | 4.70 | 10.35 | ||
Capital Group New Perspective Funbu | 13.34B | 7.78 | 3.68 | 9.31 | ||
Cap Group New Perspective lux A7 | 13.34B | 8.04 | 4.82 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Microsoft | US5949181045 | 7.17 | 406.32 | +1.82% | |
UnitedHealth | US91324P1021 | 5.20 | 495.42 | +0.32% | |
Anheuser Busch Inbev | BE0974293251 | 4.52 | 56.12 | +0.11% | |
T-Mobile US | US8725901040 | 4.50 | 163.96 | -0.05% | |
EOG Resources | US26875P1012 | 3.96 | 135.71 | +0.26% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Sell | BUY | Strong Buy |
Summary | Neutral | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review